Filing Flows › Celldex Therapeutics (CLDX) › Q1 2026 › vs Q1 2025
Celldex Therapeutics (CLDX) Q1 2026 vs Q1 2025 (year over year)
Celldex Therapeutics's revenue fell $680K (-98%) from $695K in Q1 2025 to $15K in Q1 2026.
Celldex Therapeutics, Q1 2026: revenue $15K (-98% year over year), net loss $78.7M, operating cash flow −$65.6M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $15K | $695K | −$680K | -98% |
| Other income, net | $5.8M | $8.9M | −$3.2M | -36% |
| Net loss | $78.7M | $53.8M | $24.9M | +46% |
| Costs & expenses | $84.5M | $63.4M | $21.0M | +33% |
| Operating costs | $84.5M | $63.4M | $21.0M | +33% |
| Research & development | $73.0M | $52.6M | $20.4M | +39% |
| General & admin | $11.4M | $10.8M | $629K | +6% |
| Operating cash sources | $78.7M | $53.8M | $24.9M | +46% |
| Depreciation & amortization | $854K | $867K | −$13K | -1% |
| Share-based compensation | $8.5M | $9.3M | −$793K | -9% |
| Working capital & other | $3.7M | −$10.8M | $14.5M | — |
| Cash used in operations | $65.6M | $54.4M | $11.2M | +21% |
| Net loss absorbed | $78.7M | $53.8M | $24.9M | +46% |
Questions
How much did Celldex Therapeutics's revenue grow year over year in Q1 2026?
Celldex Therapeutics's revenue fell $680K (-98%) from $695K in Q1 2025 to $15K in Q1 2026.